US Patent Issued to ENB Therapeutics on Jan. 27 for "Methods and compositions for treatment of Endothelin B receptor expressing tumors" (New York Inventor)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,533,390, issued on Jan. 27, was assigned to ENB Therapeutics Inc. (New York).

"Methods and compositions for treatment of Endothelin B receptor expressing tumors" was invented by Sumayah Jamal (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions descri...